KMDA
Kamada Ltd. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 27 | +5 | 2.57M | $19.13M | +6 | −1 |
| Q1 2026 | 22 | -3 | 2.50M | $509.41M | +1 | −4 |
| Q4 2025 | 25 | -1 | 2.61M | $442.17M | — | −1 |
| Q3 2025 | 12 | 0 | 1.99M | $13.83M | — | — |
| Q2 2025 | 9 | +2 | 1.71M | $13.25M | +2 | — |
| Q1 2025 | 6 | +2 | 1.56M | $10.32M | +2 | — |
| Q4 2024 | 4 | 0 | 1.20M | $7.32M | — | — |
| Q3 2024 | 4 | 0 | 1.28M | $6.90M | — | — |
| Q2 2024 | 4 | — | 993.01K | $4.93M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 836.30K | — | $4.15M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Millennium Management ✦ | 100.52K | — | $502,620 | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 30.30K | — | $151,520 | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 25.88K | — | $129,390 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 41 holders, 5.10M shares, $528.34M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 22.83K sh · $186,725
Director · 175 sh · $1,446
Director · 162.76K sh · $1.34M
Director · 14.24K sh · $117,891
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology